Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Blood (2021) 138 (20): 1966–1979.

https://doi.org/10.1182/blood.2021011405

Published: 2021

Includes: Supplemental data

Journal Articles

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

Jorge J. Castillo, MD, Joshua Gustine, MPH, Maria Demos, Andrew Keezer, BS, Kirsten Meid, MPH, Gloria G Chan, MS, Jiaji G Chen, Maria Luisa Guerrera, MD, Amanda Kofides, Manit Munshi, MS, Nicholas Tsakmaklis, Xia Liu, MD, Lian Xu, MS, Guang Yang, PhD, Zachary R Hunter, PhD, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 2823.

https://doi.org/10.1182/blood-2019-125069

Published: 2019

Journal Articles

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Guang Yang, PhD, Jinhua Wang, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Amanda Kofides, Lian Xu, MS, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael Gray, Steven P Treon, MD PhD FRCP

Blood (2019) 134 (Supplement_1): 394.

https://doi.org/10.1182/blood-2019-130636

Published: 2019

Journal Articles

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Xia Liu, MD, Jiaji G Chen, Manit Munshi, MS, Lian Xu, MS, Amanda Kofides, Nicholas Tsakmaklis, Maria Demos, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Cristina Jimenez, PhD, Zachary R Hunter, PhD, Christopher Patterson, Kirsten Meid, MPH, Andrew Keezer, BS, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Guang Yang, PhD

Blood (2019) 134 (Supplement_1): 3778.

https://doi.org/10.1182/blood-2019-130885

Published: 2019

Journal Articles

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

Cristina Jimenez, PhD, Gloria G Chan, MS, Lian Xu, MS, Nickolas Tsakmaklis, Jiaji G Chen, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Xia Liu, MD, Manit Munshi, MS, Joshua Gustine, MPH, Guang Yang, PhD, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Zachary R Hunter, PhD

Blood (2018) 132 (Supplement 1): 1372.

https://doi.org/10.1182/blood-2018-99-118819

Published: 2018

Journal Articles

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

Guang Yang, PhD, Jinhua Wang, PhD, Li Tan, PhD, Xia Liu, MD, Manit Munshi, MS, Jiaji G Chen, Lian Xu, MS, Nickolas Tsakmaklis, Maria Demos, Amanda Kofides, Maria Luisa Guerrera, MD, Gloria G Chan, MS, Zachary R Hunter, PhD, Christopher Patterson, MAcc, Jorge J. Castillo, MD, Sara J Buhrlage, PhD, Nathanael S. Gray, PhD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 40.

https://doi.org/10.1182/blood-2018-99-119171

Published: 2018

Journal Articles

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Zachary R Hunter, PhD, Gloria G Chan, MS, Cristina Jimenez, PhD, Nickolas Tsakmaklis, Lian Xu, MS, Jiaji G Chen, Maria Demos, Amanda Kofides, Manit Munshi, MS, Maria Luisa Guerrera, MD, Xia Liu, MD, Guang Yang, PhD, Jorge J. Castillo, MD, Ari M Melnick, MD, Steven P Treon, MD PhD FRCP

Blood (2018) 132 (Supplement 1): 1563.

https://doi.org/10.1182/blood-2018-99-119828

Published: 2018

Journal Articles

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

Amanda Kofides, Maria Demos, Nickolas Tsakmaklis, Lian Xu, MS, Xia Liu, MD, Christopher Patterson, Maria Luisa Guerrera, MD, Manit Munshi, MS, Guang Yang, PhD, Jiaji G Chen, Cristina Jimenez, PhD, Gloria G Chan, MS, Joshua Gustine, MPH, Jorge J. Castillo, MD, Steven P Treon, MD PhD FRCP, Zachary R Hunter, PhD

Blood (2018) 132 (Supplement 1): 1566.

https://doi.org/10.1182/blood-2018-99-119419

Published: 2018

Journal Articles

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

Blood (2018) 131 (18): 2047–2059.

https://doi.org/10.1182/blood-2017-10-811752

Published: 2018

Includes: Supplemental data

Journal Articles

Extracellular vesicle–mediated transfer of constitutively active MyD88 L265P engages MyD88 wt and activates signaling

Mateja Manček-Keber, Duško Lainšček, Mojca Benčina, Jiaji G. Chen, Rok Romih, Zachary R. Hunter, Steven P. Treon, Roman Jerala

Blood (2018) 131 (15): 1720–1729.

https://doi.org/10.1182/blood-2017-09-805499

Published: 2018

Includes: Supplemental data

Journal Articles

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, Jiaji G. Chen, Xia Liu, Maria Demos, Amanda Kofides, Christopher J. Patterson, Kirsten Meid, Joshua Gustine, Toni Dubeau, M. Lia Palomba, Ranjana Advani, Jorge J. Castillo, Richard R. Furman, Zachary R. Hunter, Steven P. Treon

Blood (2017) 129 (18): 2519–2525.

https://doi.org/10.1182/blood-2017-01-761726

Published: 2017

Includes: Supplemental data

Journal Articles

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Lian Xu, Nicholas Tsakmaklis, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Kirsten Meid, MPH, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Richard R. Furman, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD

Blood (2016) 128 (22): 756.

https://doi.org/10.1182/blood.V128.22.756.756

Published: 2016

Journal Articles

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2764.

https://doi.org/10.1182/blood.V128.22.2764.2764

Published: 2016

Journal Articles

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Xia Liu, MD, Jiaji G Chen, Jie Chen, PhD, Lian Xu, Nicholas Tsakmaklis, Maria Demos, Christopher J Patterson, MFA, Jorge J. Castillo, MD, Zachary Hunter, PhD, Steven P Treon, MD PhD, Guang Yang, PhD

Blood (2016) 128 (22): 2931.

https://doi.org/10.1182/blood.V128.22.2931.2931

Published: 2016

Journal Articles

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Steven P Treon, MD PhD, Nicholas Tsakmaklis, Kirsten Meid, MPH, Guang Yang, PhD, Jiaji G Chen, Xia Liu, MD, Jie Chen, PhD, Maria Demos, Christopher J Patterson, MFA, Toni Dubeau, NP, Joshua Gustine, MPH, Jorge J. Castillo, MD, Ranjana H Advani, MD, Maria Lia Palomba, MD, Lian Xu, Zachary Hunter, PhD

Blood (2016) 128 (22): 2984.

https://doi.org/10.1182/blood.V128.22.2984.2984

Published: 2016

Journal Articles

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

Zachary R. Hunter, Lian Xu, Guang Yang, Nicholas Tsakmaklis, Josephine M. Vos, Xia Liu, Jie Chen, Robert J. Manning, Jiaji G. Chen, Philip Brodsky, Christopher J. Patterson, Joshua Gustine, Toni Dubeau, Jorge J. Castillo, Kenneth C. Anderson, Nikhil M. Munshi, Steven P. Treon

Blood (2016) 128 (6): 827–838.

https://doi.org/10.1182/blood-2016-03-708263

Published: 2016

Includes: Supplemental data

Journal Articles

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Guang Yang, Sara J. Buhrlage, Li Tan, Xia Liu, Jie Chen, Lian Xu, Nicholas Tsakmaklis, Jiaji G. Chen, Christopher J. Patterson, Jennifer R. Brown, Jorge J. Castillo, Wei Zhang, Xiaofeng Zhang, Shuai Liu, Philip Cohen, Zachary R. Hunter, Nathanael Gray, Steven P. Treon

Blood (2016) 127 (25): 3237–3252.

https://doi.org/10.1182/blood-2016-01-695098

Published: 2016

Journal Articles

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

Lian Xu, Zachary Hunter, Guang Yang, PhD, Yangsheng Zhou, MD, Xia Liu, MD, Yang Cao, MD, Robert Manning, Christopher Patterson, Christina K Tripsas, MA, Sandra Kanan, NP, Jiaji G Chen, Neil I Lindeman, MD, Steven Peter Treon, MD, MA, PhD

Blood (2013) 122 (21): 3024.

https://doi.org/10.1182/blood.V122.21.3024.3024

Published: 2013

NARROW

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTK Cys481 ibrutinib resistance

Clinical and Genomic Factors Are Predictive of Response and Prognostic of Progression-Free Survival in Patients with Waldenström Macroglobulinemia Treated with Ibrutinib

A Novel HCK and BTK Dual Inhibitor Kin-8194 Shows Superior Activity over Ibrutinib and Overcomes BTK C481S Mediated Ibrutinib Resistance in Vitro and In Vivo in MYD88 Mutated B-Cell Lymphomas

Mutated MYD88 Regulates HCK Pro-Survival Signaling through JunB in MYD88 Mutated B-Lymphoma Cells

Genomic Analysis of Ibrutinib Resistance in Waldenstrom Macroglobulinemia

A Novel HCK Inhibitor Kin-8193 Blocks BTK Activity in BTK Cys481 Mutated Ibrutinib Resistant B-Cell Lymphomas Driven By Mutated MYD88

Comprehensive Integration of Whole Genome, Transcriptome and Methylation Profiling Reveals Novel Gene Dysregulation Including IL15, SOCS6 and CARD11 Associated with MYD88 and CXCR4 Genotype Status in WM

Alternative Mutations and Isoform Dysregulation in MYD88 in Waldenstrom's Macroglobulinemia

BTK Cys481Ser drives ibrutinib resistance via ERK1/2 and protects BTK wild-type MYD88-mutated cells by a paracrine mechanism

Extracellular vesicle–mediated transfer of constitutively active MyD88 L265P engages MyD88 wt and activates signaling

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Molecular Basis of Ibrutinib Resistance in Waldenstrom's Macroglobulinemia

Acquisition of BTK C481S Produces Resistance to Ibrutinib in MYD88 Mutated WM and ABC DLBCL Cells That Is Accompanied By ERK1/2 Hyperactivation, and Is Targeted By the Addition of the ERK1/2 Inhibitor Ulixertinib

HCK Transcription Is Regulated By AP1, NF-Kb and STAT3 Transcription Factors in MYD88 Mutated WM and ABC-DLBCL Cells

Mutated MYD88 Zygosity and CXCR4 Mutation Status Are Important Determinants of Ibrutinib Response and Progression Free Survival in Waldenstrom's Macroglobulinemia

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia

HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib

Detection Of MYD88 L265P In Peripheral Blood Of Patients With Waldenström's Macroglobulinemia and IgM Monoclonal Gammopathy Of Undetermined Significance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only